Featured Research

from universities, journals, and other organizations

Space Research May Accelerate Development Of Flu-Fighting Drug

Date:
March 12, 1999
Source:
Marshall Space Flight Center
Summary:
Even with vaccines, 20-40 million people in the United States catch the flu each year, and thousands are at risk of dying from its complications. In the future, a new class of prescription drugs called neuraminidase inhibitors offers the prospect for decreasing the duration and severity of the illness and may even prevent the development of symptoms in those exposed to the virus. One of these neuraminidase inhibitors was developed through ground and space research conducted in partnership by NASA and the Center for Macromolecular Crystallography at the University of Alabama at Birmingham.

Even with vaccines, 20-40 million people in the United States catch the flu each year, and thousands are at risk of dying from its complications.

In the future, a new class of prescription drugs called neuraminidase inhibitors offers the prospect for decreasing the duration and severity of the illness and may even prevent the development of symptoms in those exposed to the virus. One of these neuraminidase inhibitors was developed through ground and space research conducted in partnership by NASA and the Center for Macromolecular Crystallography at the University of Alabama at Birmingham.

The compound was synthesized by BioCryst Pharmaceuticals in Birmingham, Ala., and is now under development by The R.W. Johnson Pharmaceutical Research Institute in Raritan, N.J., a Johnson & Johnson company.

"With the aid of NASA support for space and ground-based research, we successfully mapped the molecular structure of the influenza virus -- exposing its weaknesses," said Dr. Larry DeLucas, director of the Center for Macromolecular Crystallography at the University of Alabama at Birmingham.

Sponsored by the Space Product Development Office of NASA's Microgravity Research Program at the Marshall Space Flight Center in Huntsville, Ala., DeLucas' organization is chartered as a NASA Commercial Space Center -- encouraging private industry to benefit from space technology. Dr. Ming Luo, a professor of the Center for Macromolecular Crystallography, and an international team of crystallographers, developed the "molecular map" of the flu virus using space-grown protein crystals.

Influenza protein crystals flown aboard Space Shuttle mission STS-77 in May 1996 were used to confirm earlier studies and to determine the effectiveness of potential drugs on the flu virus protein.

"By analyzing space-grown crystals of the influenza virus, we were able to get a clearer picture of the virus' structure," said DeLucas. "NASA's support for this research project probably saved considerable time needed to develop this new drug."

Called "structure-based drug design," this research focuses on how molecules of a virus fit together. Researchers built diagrams of the flu's unique shape to design drugs that block the undesirable characteristics of the virus.

Neuraminidase inhibitors are designed to block an active site of influenzaneuraminidase, an enzyme associated with the spread of the flu. Unlike vaccines, which have to be taken before exposure and are only specific to certain strains of the influenza virus, neuraminidase inhibitors may be taken as either treatment or prevention, and are effective against a wide variety of influenza strains.

"It's like trying to build a tiny key that fits into a tiny lock," said DeLucas. "Except this lock is living, breathing, flexing, changing temperatures and in constant motion."

The R.W. Johnson Pharmaceutical Research Institute is responsible for all phases of testing the drug in humans. Before becoming available in the U.S., the drug must undergo this testing and be approved by the Food and Drug Administration.

Pure, precisely ordered protein crystals of large size and uniformity are in high demand by drug developers for efforts such as this flu research. When grown on the ground, protein crystals often cannot be grown as large or as well ordered as researchers desire, obscuring these vital pathways to a better understanding of disease. As the "frequent flyers" of the space program, protein crystal growth experiments are aboard nearly every Space Shuttle mission, helping researchers unlock the secrets of how to stop infection and disease on Earth.

Space research has provided important advances in the understandingof many diseases, including heart disease, cancer, diabetes, respiratorysyncytial virus and hepatitis.

Note to Editors: Interviews are available with NASA, industry and university researchers by contacting Steve Roy of the Marshall Center Media Relations Office at (256) 544-6535. More information about NASA's Microgravity Research Program experiments can be found at: http://www.msfc.nasa.gov/news and http://microgravity.msfc.nasa.gov

Photos: Contact Steve Roy to receive the three available photos or download print-quality images from the web at: http://www1.msfc.nasa.gov/NEWSROOM/news/photos/1999/photos99-040.htm

#9901148 (Flu Diagram) Mapping a Disease Brings Hope for Relief from the Flu

Developed from flu crystals grown in space, a computer model shows where a new drug (in yellow and purple) may be attached to the flu virus to stop it from spreading.

#9901150 (Luo with model) Fighting the Flu with Help from Space

Because of the increased size and perfection of space-grown crystals of the flu virus, Dr. Ming Luo, associate director of the Center for Macromolecular Crystallography of the University of Alabama at Birmingham, has designed a molecular model of a new anti-flu drug.

#9901149 (Luo with crystals) Space Crystals May Help Fight the Flu

By X-raying flu virus crystals grown in space, Dr. Ming Luo, associate director of the Center for Macromolecular Crystallography located at the University of Alabama at Birmingham, is able to map the flu’s structure for drug developers.

- end -


Story Source:

The above story is based on materials provided by Marshall Space Flight Center. Note: Materials may be edited for content and length.


Cite This Page:

Marshall Space Flight Center. "Space Research May Accelerate Development Of Flu-Fighting Drug." ScienceDaily. ScienceDaily, 12 March 1999. <www.sciencedaily.com/releases/1999/03/990311125525.htm>.
Marshall Space Flight Center. (1999, March 12). Space Research May Accelerate Development Of Flu-Fighting Drug. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1999/03/990311125525.htm
Marshall Space Flight Center. "Space Research May Accelerate Development Of Flu-Fighting Drug." ScienceDaily. www.sciencedaily.com/releases/1999/03/990311125525.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins